12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Hylenex: Phase IV data

Interim data from 11 evaluable Type I diabetics in a double-blind, crossover, U.S. Phase IV trial showed that pretreatment with subcutaneous Hylenex before sensor augmented insulin analog pump (SAP) therapy significantly improved mean post-prandial glucose control at hours 1 (143 vs. 184 mg/dL,...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >